Baggers J, Johnsen H E
Medicinsk haematologisk afdeling L, Amtssygehuset i Herlev.
Ugeskr Laeger. 1998 Sep 14;160(38):5505-8.
A retrospective analysis of the outcome for 283 haematological patients who relapsed after high dose chemotherapy and autologous stem cell transplantation during a five year period from 1989 to 1994 is presented. The patients were treated in accordance with local regimes at 20 Nordic transplantation centers and included patients with acute leukemia (157 patients), multiple myeloma (16 patients) and lymphoma (110 patients). Two hundred and twenty-nine patients with relapse or progressive disease were given chemo- and/or radiotherapy and the response was evaluated after 90 days. Fifty-four patients (24%) obtained a complete remission and 44 patients (19%) partial remission. The overall median survival after relapse was five months. In the group who received salvage treatment the median survival was seven months, and for the 54 patients in complete remission the median survival was 15 months. We found that survival after relapse depends upon primary disease, the time from transplantation to relapse and whether salvage therapy was initiated.
本文对1989年至1994年五年间283例接受大剂量化疗和自体干细胞移植后复发的血液学患者的治疗结果进行了回顾性分析。这些患者在20个北欧移植中心按照当地治疗方案接受治疗,包括急性白血病患者(157例)、多发性骨髓瘤患者(16例)和淋巴瘤患者(110例)。229例复发或疾病进展的患者接受了化疗和/或放疗,并在90天后评估疗效。54例患者(24%)获得完全缓解,44例患者(19%)获得部分缓解。复发后的总体中位生存期为5个月。在接受挽救治疗的患者组中,中位生存期为7个月,而54例完全缓解的患者中位生存期为15个月。我们发现复发后的生存取决于原发疾病、从移植到复发的时间以及是否开始挽救治疗。